Free Trial

Royalty Pharma (RPRX) Insider Trading & Ownership

Royalty Pharma logo
$24.92 +0.64 (+2.64%)
(As of 12/20/2024 05:51 PM ET)

Royalty Pharma (NASDAQ:RPRX) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
18.90%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
2
Amount Of
Insider Selling
(Last 12 Months)
$8.86 M
Get RPRX Insider Trade Alerts

Want to know when executives and insiders are buying or selling Royalty Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

RPRX Insider Buying and Selling by Quarter

Royalty Pharma Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2024Rory B RiggsDirectorSell35,702$27.55$983,590.10  
1/2/2024Rory B RiggsDirectorSell235,200$28.52$6,707,904.00  
12/27/2023Avara Management LtdMajor ShareholderSell41,729$28.01$1,168,829.29  
(Data available from 1/1/2013 forward)

RPRX Insider Trading Activity - Frequently Asked Questions

The list of insiders at Royalty Pharma includes 1978 Sicaf Sif S.A. - Gg St Gg, 1978 Sicaf Sif S.A. Gg, Avara Management Ltd, George W Lloyd, Henry A Fernandez, James F Reddoch, Mario Germano Giuliani, Marshall Urist, Pablo G Legorreta, Rory B Riggs, and Terrance P Coyne. Learn more on insiders at RPRX.

18.90% of Royalty Pharma stock is owned by insiders. Learn more on RPRX's insider holdings.

The following insider purchased RPRX shares in the last 24 months: Pablo G Legorreta ($15,543,025.16).

Insiders have purchased a total of 485,388 RPRX shares in the last 24 months for a total of $15,543,025.16 bought.

The following insiders have sold RPRX shares in the last 24 months: Avara Management Ltd ($1,168,829.29), George W Lloyd ($7,509,502.58), Marshall Urist ($870,320.90), Rory B Riggs ($65,493,259.80), and Terrance P Coyne ($2,317,125.00).

Insiders have sold a total of 2,384,012 Royalty Pharma shares in the last 24 months for a total of $77,359,037.57 sold.

Royalty Pharma Key Executives

  • Mr. Pablo Gerardo Legorreta (Age 60)
    Founder & Chief Executive Officer and Chairman
  • Mr. Terrance P. Coyne
    Executive VP & CFO
  • Mr. George Wingate Lloyd (Age 64)
    Executive VP of Investments & Chief Legal Officer
    Compensation: $4.56M
  • Mr. Christopher Hite (Age 56)
    Vice Chairman & Executive VP
    Compensation: $4.56M
  • Dr. Marshall Jonathan Urist M.D. (Age 48)
    Ph.D., Executive Vice President of Research & Investments
    Compensation: $4.56M
  • Mr. Arthur Richard McGivern J.D.
    Executive Vice President of Investments & General Counsel
  • Mr. Ashwin Pai M.D.
    Executive Vice President of Investments
  • Ms. Kristin Stafford (Age 42)
    Senior VP & Chief Accounting Officer
  • Mr. Eric Cornelius Schneider
    Senior VP & Chief Technology Officer
  • Dr. James Folmar Reddoch Ph.D. (Age 54)
    Executive VP of Investments & Chief Scientific Officer
    Compensation: $3.4M


This page (NASDAQ:RPRX) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners